These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 27896916)

  • 1. Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
    Xu W; Lu C; Zhang F; Shao J; Yao S; Zheng S
    FEBS J; 2017 Jan; 284(1):114-133. PubMed ID: 27896916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR-S1PR2-dependent mechanism.
    Xu W; Lu C; Zhang F; Shao J; Zheng S
    IUBMB Life; 2016 May; 68(5):376-87. PubMed ID: 27027402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
    Verbeke L; Mannaerts I; Schierwagen R; Govaere O; Klein S; Vander Elst I; Windmolders P; Farre R; Wenes M; Mazzone M; Nevens F; van Grunsven LA; Trebicka J; Laleman W
    Sci Rep; 2016 Sep; 6():33453. PubMed ID: 27634375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
    Fan YY; Ding W; Zhang C; Fu L; Xu DX; Chen X
    Int Immunopharmacol; 2019 Dec; 77():105911. PubMed ID: 31671330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.
    Carino A; Biagioli M; Marchianò S; Scarpelli P; Zampella A; Limongelli V; Fiorucci S
    Pharmacol Res; 2018 May; 131():17-31. PubMed ID: 29530598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatoprotection of yangonin against hepatic fibrosis in mice via farnesoid X receptor activation.
    Wang X; Fu T; Wang J; Wang C; Liu K; Wu J; Sun H; Ma X; Sun P; Meng Q
    Int Immunopharmacol; 2019 Oct; 75():105833. PubMed ID: 31450152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probucol ameliorates hepatic stellate cell activation and autophagy is associated with farnesoid X receptor.
    Yang R; Hu Z; Zhang P; Wu S; Song Z; Shen X; Wei Z
    J Pharmacol Sci; 2019 Feb; 139(2):120-128. PubMed ID: 30638990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner.
    Xu W; Lu C; Yao L; Zhang F; Shao J; Zheng S
    Toxicol Appl Pharmacol; 2017 Jan; 315():23-34. PubMed ID: 27939985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docosahexaenoic acid attenuates carbon tetrachloride-induced hepatic fibrosis in rats.
    He J; Bai K; Hong B; Zhang F; Zheng S
    Int Immunopharmacol; 2017 Dec; 53():56-62. PubMed ID: 29035816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
    J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrf2 knockdown attenuates the ameliorative effects of ligustrazine on hepatic fibrosis by targeting hepatic stellate cell transdifferentiation.
    Lu C; Xu W; Zhang F; Shao J; Zheng S
    Toxicology; 2016 Jul; 365():35-47. PubMed ID: 27477297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
    Zhou J; Cui S; He Q; Guo Y; Pan X; Zhang P; Huang N; Ge C; Wang G; Gonzalez FJ; Wang H; Hao H
    Nat Commun; 2020 Jan; 11(1):240. PubMed ID: 31932588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction between autophagy and senescence is required for dihydroartemisinin to alleviate liver fibrosis.
    Zhang Z; Yao Z; Zhao S; Shao J; Chen A; Zhang F; Zheng S
    Cell Death Dis; 2017 Jun; 8(6):e2886. PubMed ID: 28617435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis.
    Ling L; Li G; Wang G; Meng D; Li Z; Zhang C
    Mol Med Rep; 2019 Aug; 20(2):1605-1612. PubMed ID: 31257490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatoprotection of auraptene from peels of citrus fruits against thioacetamide-induced hepatic fibrosis in mice by activating farnesoid X receptor.
    Gao X; Wang C; Ning C; Liu K; Wang X; Liu Z; Sun H; Ma X; Sun P; Meng Q
    Food Funct; 2018 May; 9(5):2684-2694. PubMed ID: 29721568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROS-JNK1/2-dependent activation of autophagy is required for the induction of anti-inflammatory effect of dihydroartemisinin in liver fibrosis.
    Zhang Z; Guo M; Zhao S; Shao J; Zheng S
    Free Radic Biol Med; 2016 Dec; 101():272-283. PubMed ID: 27989749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of the nuclear high mobility group B1 peptides released from injured hepatocytes in murine hepatic fibrogenesis.
    Kao YH; Lin YC; Tsai MS; Sun CK; Yuan SS; Chang CY; Jawan B; Lee PH
    Biochim Biophys Acta; 2014 Sep; 1842(9):1720-32. PubMed ID: 24970745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alisol B 23-acetate protects against non-alcoholic steatohepatitis in mice via farnesoid X receptor activation.
    Meng Q; Duan XP; Wang CY; Liu ZH; Sun PY; Huo XK; Sun HJ; Peng JY; Liu KX
    Acta Pharmacol Sin; 2017 Jan; 38(1):69-79. PubMed ID: 27773935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dihydroartemisinin prevents liver fibrosis in bile duct ligated rats by inducing hepatic stellate cell apoptosis through modulating the PI3K/Akt pathway.
    Chen Q; Chen L; Wu X; Zhang F; Jin H; Lu C; Shao J; Kong D; Wu L; Zheng S
    IUBMB Life; 2016 Mar; 68(3):220-31. PubMed ID: 26865509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
    Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
    Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.